Uses of Oziapanto

Oziapanto is a selective proton pump inhibitor, used in the treatment of peptic ulcers and gastroesophageal reflux disease. Unlike many gastrointestinal drugs, Oziapanto is administered as an injection, so patients need to understand Oziapanto before taking it.

Oziapanto is a medicine used to treat gastrointestinal diseases, specifically gastroesophageal reflux diseases caused by duodenal ulcers. Oziapanto is made in the form of a vial of powder for injection, with the main ingredient being Pantoprazol Sodium, each bottle of Oziapanto contains 40mg of Pantoprazol Sodium. Administer Oziapanto intravenously.

The main use of Oziapanto is to selectively inhibit the proton pump, so Oziapanto is used in the treatment of diseases where the stomach secretes a lot of gastric acid, uncontrolled. Pantoprazole is the main ingredient of the drug Oziapanto, which is a chemical derivative of benzimidazole. The main effect of Pantoprazole is to penetrate the acid-secreting tubules of gastric parietal cells, converting it to active sulfenamide, which will irreversibly bind to the enzyme H=/K+ATPase (also known as proton pump enzyme). ) is present on the surface of gastric parietal cells. By causing this enzyme to be inhibited, acid secretion into the stomach wall is stopped. The outstanding point of Pantoprazole is that it helps the stomach not to secrete acid even if it is stimulated by any agent. But the effect of Oziapanto drug depends on the dose that is loaded into the body. At usual doses, Oziapanto's inhibitory effect on acid secretion persists for 24 hours. According to clinical reports, when patients take drugs containing Pantoprazole orally and parenterally, the parenteral route has a faster effect. With an injection dose of 20mg - 120mg, the drug will start to work after 15 - 30 minutes of injection. The gastric acid secreting effect lasts for 24 hours. The main ingredient Pantoprazole in Oziapanto is rapidly absorbed and reaches peak concentrations fairly quickly when administered parenterally. Bioavailability of the drug is above 77% (77% is for oral administration). Oziapanto is strongly bound with 98% of the dose bound to plasma proteins. Regarding the extent of elimination, Oziapanto has an elimination half-life of 0.7 - 1.9 hours, this time can be extended from 3 to 6 hours in patients with liver failure or slow drug metabolism due to genetic factors. Excreted mainly by the kidneys and partly in the faeces.

In peptic ulcer disease or disease in which gastric parietal cells secrete a lot of gastric acid, Oziapanto is indicated for use in patients. Or, depending on the severity of the disease, it is necessary to use drugs with rapid proton pump inhibitors.
Patients with gastroesophageal reflux disease - oesophagitis. Patients with gastric and duodenal ulcers. Using Oziapanto in the prevention of gastric and duodenal ulcers caused by patients taking non-steroidal anti-inflammatory drugs. Conditions of increased gastric acid secretion such as Zollinger-Ellison syndrome.

The use of Oziapanto is contraindicated in patients with a history of hypersensitivity to any of the ingredients listed in the instruction manual.

How to use: Oziapanto can be used intravenously, intravenously.
If used intravenously, mix Oziapanto 40mg powder vial with 10ml 0.9% NaCl solution, perform slow intravenous injection for 2 minutes. Intravenous infusion: Mix Oziapanto 40mg vial with 100ml 0.9% NaCl solution or 5% dextran, or Ringer Lacate. The duration of intravenous Oziapanto infusion is 15 minutes. Notes on injection and intravenous infusion: Do not mix or use the same line with drugs that the patient has infused before. If a dose of 20mg is used, mix it with half of the solutions mentioned above. Solution not used for reconstitution should be discarded. Dosage:
Peptic ulcer disease, severe gastro-oesophageal reflux disease: 40mg each time (1 bottle of Oziapanto), once a day People with severe liver failure: You can choose to reduce the dose or use it every other day. Maximum dose 20 mg/day (half a vial/day) or 2 days use 1 vial of 40mg Kidney failure: Use the same dose as normal Children: Oziapanto should not be used in this person because the safety has not been tested. determined. The duration of treatment with Oziapanto is very short. Patients should switch to oral therapy when symptoms subside.

The most commonly reported side effects in patients using it are nausea, diarrhea and headache. More serious manifestations may include skin rash, itching, and dizziness.
Rarely, reactions such as basal edema, fever and thrombophlebitis occur.
Note when using Oziapanto
Before using Oziapanto in particular and other proton pump inhibitors, it is necessary to understand the patient's history and exclude the possibility of stomach cancer. Because proton pump inhibitors can mask symptoms, making the diagnosis of cancer inaccurate. Use Oziapanto with caution in people with liver disease (acute and chronic hepatitis, liver cancer). When used in this subject, the serum concentration of Oziapanto may be slightly increased and its elimination may be reduced. For people with cirrhosis or severe liver failure, Oziapanto should not be used. In case of necessity, it is recommended to use the dose every other day or reduce the dose by half in combination with monitoring the patient's liver function. Oziapanto should be used with caution in the elderly and in patients with renal impairment. During pregnancy, Oziapanto should be used when absolutely necessary, because there is a risk of retardation of fetal bone growth. It is not known whether the ability to be excreted in human milk or not, however, according to studies in rats, the active ingredient pantoprazole has a risk of causing cancer in rats. Therefore, it is not recommended to use Oziapanto while breastfeeding. Oziapanto is a proton pump inhibitor used in the treatment of gastroesophageal reflux disease, gastritis, duodenal ulcer. With the main active ingredient Pantoprazol, Oziapanto is administered by injection, the patient must adhere to the dose prescribed by the doctor.